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How should you manage 
a depressed patient 
unresponsive to an SSRI?
The best approach among studied 
alternatives to manage a patient with 
treatment-resistant depression is not clear
from the evidence. All of the options
reviewed seem to have about a 25% 
to 30% success rate.
Switching to other antidepressants 
or augmenting with non-antidepressant
drugs has the best supporting evidence
(strength of recommendation [SOR]: B).1
Adding additional antidepressants 
(SOR: B), using psychotherapy (SOR: B),
and initiating electroconvulsive therapy
(ECT) (SOR: C) are options. Various 
antidepressants are used as add-on 
therapy. Psychotherapy is often 
recommended, though the evidence of
benefit after a failed course of initial 
therapy is sparse. The evidence supporting
use of ECT in treatment-resistant 
depression is weak.
Comparison among the options is 
based on expert opinion (SOR: C).
Additional reports from the STAR*D trial
may improve the quality of the evidence 
in the near future.
E V I D E N C E - B A S E D A N SW E R
Optimize initial drug dose and duration,
then change to a different medication 
if needed
Although “epidemics” of obesity and 
avian influenza steal headlines, depression
remains an American scourge, with a life-
time prevalence of 13% and rising. Major 
depressive disorder is often a chronic or
relapsing illness, with recurrence rates 
of more than 40% at 2 years. Treatment
resistance may be associated with pain
(which is a presenting symptom in two
thirds of depressed patients), psychosocial
factors, psychiatric comorbidities, or the
presence of bipolar disorder rather than
unipolar depression.
Various forms of counseling and 
psychotherapy, alone or in combination 
with medications, are effective in treating
depression, and I recommend them liberally
when resources permit. Like the authors of
this review, I first optimize initial drug dose
and duration, then change to a different
medication if needed. Some evidence 
suggests benefit from a combined serotonin
and norepinephrine agent, such as 
venlafaxine (Effexor) or imipramine (Tofranil),
which may also alleviate pain. I often add a 
noradrenergic tricyclic antidepressant, such
as nortriptyline or desipramine, or the newer
agent mirtazapine (Remeron), to a selective
serotonin reuptake inhibitor (SSRI) for 
augmentation. I encourage physicians not to
fear tricyclics, although I am hesitant to use
lithium, thyroxine, or atypical antipsychotics
in depression because of their hazards.
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z Evidence summary
In general, strategies for addressing treat-
ment-resistant depression have not been
compared in head-to-head studies. Guide-
lines at this time are based mainly on
expert opinion2,3 and gradually accumulat-
ing data from a few randomized controlled
studies or low-quality cohort studies. 
While it makes sense, as the question
implies, to first optimize the dose and
duration of SSRI treatment in treatment-
resistant depression, it is not clear which
strategy to employ next. Switch, augmen-
tation, and combination strategies may
each improve clinical outcomes, but which
strategy is best is based on expert opinion
at this time.
Optimize. The first step in treatment-
resistant depression should be optimizing
dose and duration of therapy.4 For fluoxe-
tine (Prozac), based on a nonrandomized
open trial, patients should receive 8 weeks
of treatment before the SSRI course is
deemed adequate. Only 23% of patients
who have not responded to 8 weeks of flu-
oxetine respond to a still longer course of
fluoxetine.
Switch. The strongest evidence is from
the recent STAR*D trial, a randomized
study that assigned patients in one arm of
the study who had no relief from (or did
not tolerate) therapy with citalopram
(Celexa) to 1 of 3 drugs—sustained-release
bupropion (Wellbutrin SR), sertraline
(Zoloft), or extended-release venlafaxine
(Effexor XR). The study concluded that
approximately 1 in 4 patients have remis-
sion after switching to an antidepressant
from another drug class.1 Further switches
in antidepressant monotherapy have a low
success rate (10%–20%).5
Add/combine. Mixed evidence sup-
ports combining different antidepressants.
There is cohort study evidence that com-
bining citalopram and bupropion is more
effective than switching to the alternate
antidepressant,6 but other cohort studies
did not find a significant difference
between switching and augmenting. An
arm of the STAR*D trial added either sus-
tained-release bupropion or buspirone
(Buspar) to the failed citalopram therapy.
Thirty percent of patients with depression
unresponsive to citalopram had remission
when bupropion-SR or buspirone was
added.7 The STAR*D reports do not 
compare the 2 strategies of switching or
combining drugs directly.
Augment. Evidence from a meta-analy-
sis with aggregate data from 3 studies rep-
resenting a total of 110 patients showed
that augmentation of various antidepres-
sants with lithium leads to improved 
outcomes (number needed to treat
[NNT]=3.7).8 A cohort study of augmenta-
tion with an atypical antipsychotic agent
such as aripiprazole (Abilify) suggest
improved outcomes, but similar studies
found no benefit.9 A small (23-patient)
randomized trial of lamotrigine (Lamictal)
suggests that it may augment the effect of
fluoxetine.10
Psychotherapy. A systematic review of
psychological therapies in treatment-resist-
ant depression found 2 controlled studies
(of cognitive therapy and cognitive behav-
ioral therapy) out of 12 total studies meet-
ing their inclusion criteria that demonstrat-
ed improved scores on the Hamilton
Rating Scale for Depression. Further study
of these therapies was recommended.11
ECT. The evidence supporting use of
ECT for treatment-resistant depression
comes from studies following failure of
treatment with tricyclic antidepressants
and monoamine oxidase (MAO)
inhibitors. Methodological problems in
these older studies do not permit an esti-
mate of response rate.12
Recommendations by others
The American Psychiatric Association
treatment guideline recommends changing
antidepressant, adding or changing to psy-
chotherapy, or ECT if no response to 4 to
8 weeks of the initial therapy in depres-
sion.13 A guideline from the University of
Michigan recommends referral to a psychi-
atrist if patients have treatment refractory
depression (defined in their guideline as
failure of 2 successive trials of antidepres-
sants).14 The Institute for Clinical Systems
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Improvement guideline recommends con-
sidering switch, augmentation, or other
therapies (including adding or modifying
psychotherapy).15
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